GRB2 and breast carcinoma: Silencing GRB2 inhibited cell proliferation and invasion [17]; LMTK3 kinase facilitated the invasion of breast cancer by inducing integrin β1 through GRB2‐mediated paths [18]; and MiR‐27b directly targeted CBLB and GRB2 to deactivate the MAPK pathways, which improved the response to paclitaxel [19].